A phase II study of PAD therapy (bortezomib, doxorubicin, and dexamethasone) for relapsed or refractory multiple myeloma.
Phase of Trial: Phase II
Latest Information Update: 12 May 2016
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 11 Sep 2012 New trial record